Eli Lilly shares topline results from LIBRETTO-531 trial for Retevmo

Betsy Goodfellow | August 23, 2023 | News story | Research and Development Eli Lilly, Oncology, Retevmo, clinical trial, slpercatinib, thyroid cancer 

Eli Lilly has announced topline results from the LIBRETTO-531 study assessing Retevmo (selpercatinib) as an initial treatment for patients with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC).

The trial compared Retevmo with multikinase inhibitors (MKIs) cabozantinib or vendetanib for this indication, and met its primary endpoint, meaning it demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS).

LIBRETTO-531 was the first randomised trial to compare the safety and effectiveness of a highly selective RET-kinase inhibitor versus MKIs for this indication.

David Hyman, MD, chief medical officer of Loxo@Lilly, commented: “These data from the LIBRETTO-531 trial confirm the importance of selectivity in targeting RET-driven cancers and suggest Retevmo should be considered the preferred first-line treatment for people with advanced RET-mutant medullary thyroid cancer. Taken together with the recent positive Retevmo Phase 3 LIBRETTO-431 announcement in lung cancer, these results underscore the importance of timely and broad-based genomic testing to ensure patients who could potentially benefit receive targeted therapies. We look forward to sharing detailed data with the oncology community.”

Full results of this trial are expected to be presented at an upcoming medical meeting, submitted to a peer-reviewed journal and ultimately discussed with the relevant health authorities.

Betsy Goodfellow

Related Content

AstraZeneca shares positive interim results from phase 3 lymphoma trial

AstraZeneca has announced positive high-level results from an interim analysis of the ECHO phase 3 …

Verona Pharma to share phase 3 COPD trial data at ATS 2024

Verona Pharma has announced that it will share eight posters at the American Thoracic Society …

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

Eli Lilly and Nexus Pharmaceuticals have announced that they have entered into a definitive agreement …

Latest content